Nuclear factor of activated T cells (NFAT) was originally described as a T-cell-specific transcription factor that supported the activation of cytokine gene expression and mediated the immunoregulatory effects of cyclosporin A ICsA). As we observed that activated endothelial cells also expressed NFAT, we tested the antiinflammatory properties of CsA in endothelial cells. Significantly, CsA completely suppressed the induction of NFAT in endothelial cells and inhibited the activity of granulocyte-macrophage colony-stimulating factor (GM-CSF) gene regulatory elements that use NFAT by 60%. CsA similarly mediated a reduction of up to 65% in GM-CSF mRNA and protein expression in activated endothelial cells. CsA also suppressed E-selectin, but not vascular cell adhesion molecule-l (VCAM-1) expression in HE REGULATION of cytokine gene expression is central to the regulation of the immune response.',2 The T cell has been the most intensively studied model system for investigating cytokine gene regulation, as a wide variety of cytokines are induced on activation of the T-cell receptor.' The transcription factor nuclear factor of activated T cells (NFAT)'.3-7 plays a key role in the activation of many of these genes and is itself induced on T-cell receptor activation. The induction of cytokines such as interleukin-2 (IL-2) and granulocyte-macrophage colony-stimulating factor (GM-CSF) in T cells can be suppressed by cyclosporin A (CsA), and these effects are largely caused by the ability of CsA to inhibit activation of NFAT.',5*6,s,9 Furthermore, the immunosuppressive actions of CsA have been widely attributed to its ability to suppress T-cell expression of cytokines such as IL-2, and hence T-cell activation and proliferation.
HE REGULATION of cytokine gene expression is central to the regulation of the immune response.',2 The T cell has been the most intensively studied model system for investigating cytokine gene regulation, as a wide variety of cytokines are induced on activation of the T-cell receptor. ' The transcription factor nuclear factor of activated T cells (NFAT)'.3-7 plays a key role in the activation of many of these genes and is itself induced on T-cell receptor activation. The induction of cytokines such as interleukin-2 (IL-2) and granulocyte-macrophage colony-stimulating factor (GM-CSF) in T cells can be suppressed by cyclosporin A (CsA), and these effects are largely caused by the ability of CsA to inhibit activation of NFAT.',5*6,s,9 Furthermore, the immunosuppressive actions of CsA have been widely attributed to its ability to suppress T-cell expression of cytokines such as IL-2, and hence T-cell activation and proliferation.
NFAT, initially thought to be a T-cell specific factor, typically consists of a complex of AP-1 family proteins and NFATp or NFATc, which are respectively induced via protein kinase C and Ca2+ signals originating from T-cell receptor activation.*-" NFATp and NFATc are related proteins4." that are expressed in the cytoplasm of T cells and translocate to the nucleus in response to the Ca2' activation of the CsAinhibitible phosphatase calcine~rin.~.'~.'~'~ Hence, NFATp and NFATc are major targets for the actions of CsA in T cells. The genes for NFATp and NFATc have recently been c l~n e d~. '~, '~ and it is now believed that NFATc is largely restricted to lymphoid tissues, while NFATp expression is more widespread.
NFAT contributes to the activation of the GM-CSF locus in T cells by interacting with four strong binding sites in an upstream and two weak binding sites in the GM-CSF However, GM-CSF is also expressed at sites of inflammation in many cell types other than T cells.z~22 This raises the possibility that induction of GM-CSF expression in these cell types could also require NFAT. Consequently, the GM-CSF locus may also be a target for CsA in cells such as activated endothelial cells that express GM-CSF.
The endothelial cell represents the interface between the hematopoietic compartment where immune effector cells originate and tissues where primary immune responses occur, and endothelial cells play a direct role in governing the traffic of leukocytes across the e n d o t h e l i~m .~~.~~ On activation, endothelial cells produce numerous cytokines, including GM-CSF, which activate immune response effector cells such as neutrophils, monocytes, basophils, and eosinotors of acute and chronic inflammatory conditions such as rheumatoid arthritis, asthma, and GM-CSF is typically induced in endothelial cells by proinflammatory cytokines such as tumor necrosis factor-a (TNF-a) and IL-1 and its expression is regulated at both transcriptional and posttranscriptional le~els.2~ Agents that activate the protein kinase C and Ca2+ pathways in endothelial cells would also be expected to induce GM-CSF expression.
In addition to producing cytokines, activated endothelial cells also express the cell surface adhesion molecules Eselectin, P-selectin, vascular cell adhesion molecule-l (VCAM-l), and intercellular adhesion molecule-l (ICAMl), which mediate recruitment and transmigration of leukocytes across the e n d~t h e l i u m . '~~~~"~ E-selectin (previously termed ELAM-l) is a cell surface glycoprotein found exclu-sively on endothelial cells that interacts with receptors on a subset of leukocytes that include neutrophils, eosinophils, monocytes, and a subset of memory T cells.24 E-selectin is involved in the earliest stages of leukocyte recruitment as it mediates the initial tethering and rolling of leukocytes across the end~thelium.'~ Acute and chronic inflammatory conditions are typically maintained by the activation of both cytokines and adhesion molecules that function in concert to orchestrate the interactions between numerous participating cell types. Elevated expression of E-selectin, for example, is associated with inflammatory conditions such as a~thma,~' rheumatoid arthritis,32 and psoriasis.33 While CsA is more commonly used as an immunosuppressive agent to prevent organ transplant rejection, it has also been found to be effective in the treatment of a variety of chronic inflammatory and autoimmune disorders such as psoriasis," asthma,27 ulcerative ~olitis,'~ and rheumatoid arthriti~.~' While some of the benefits of these treatments can be attributed to actions against T cells, there may be additional direct effects on either the activation or trafficking of cell types such as neutrophils, eosinophils, and monocytes.
To gain a better understanding of the involvement of the endothelium in inflammation, we have investigated the regulation of the GM-CSF and E-selectin genes in endothelial cells. For this purpose we have used passaged human umbilical vein endothelial cells (HUVEs) and the recently derived endothelial cell line C11STH.36 We initially cloned Cl lSTH cells from a spontaneous transformant that arose in a culture of HUVEs and showed that they have a repertoire of adhesion molecules and TNF-a receptors similar to that found in normal H U V E S .~~ In this study we found that, as in T cells, the GM-CSF enhancer was required for efficient activation of the GM-CSF promoter in endothelial cells. Interestingly, these effects appeared to be mediated in part by the transcription factor NFAT. Furthermore, NFAT and GM-CSF induction in endothelial cells was suppressed by CsA. The induction of Eselectin in endothelial cells and acquired ability to support neutrophil adhesion were also inhibited by CsA, suggesting a wider role for this drug in combating inflammation. In the course of these studies we established that the endothelial cell line C1 lSTH36 is a valuable model system for studying inflammatory events in the endothelium.
MATERIALS AND METHODS

Reagents.
The phorbol ester phorbol 12-myristate 13-acetate (PMA) was purchased from Sigma (St Louis, MO), the calcium ionophore A23 187 (I) was purchased from Boehringer (Mannheim, Germany), forskolin was purchased from Calbiochem (San Diego, CA), cyclosporin A (CsA) was a gift from Sandoz (Basel, Switzerland), DNase1 was purchased from Worthington (Freehold, NJ), and TNF-a and interferon-? (IFN-y) were provided by Genetech (San Francisco, CA). PMA was prepared as a I-mg/mL stock in dimethyl sulfoxide (DMSO), A23187 as a 20-mmoUL stock in DMSO, forskolin as a IO-mmoVL stock in DMSO, and CsA as a l-mmoVL stock in ethanol.
Oligonucleotides. Oligonucleotide duplexes used as probes and competitors had the following sequences, with complementary single stranded regions at each end shown in lower case for the upper strand only: GM430, gatcTCACACATCTTTCTCATGGAA-AGATGA; IL-2 NFAT, gatcCGAAAGGAGGAAAAACTGI7-l-
CATACAGAAG;X,TCGCCAATGAGCTCCCGGGTCGACTGC-
CCATCT; E-selectin NF-KB, aattCGTTTTTGGATGCCATG-GGGATTTCCTCTTTACTGGATGTG. The GM430 sequence is a high affinity NFATp/c binding site located in the GM-CSF enhan~er.'.~ Plasmids. The luciferase reporter gene plasmid pGMluc3' had a 655-bp fragment of the human GM-CSF promoter (-627 to +28) upstream of the luciferase gene. The plasmid pGMEluc has a 716-bp BglII fragment of the human GM-CSF enhancer placed upstream of the GM-CSF promoter in the BglII site of pGMluc.
Cell culture. C1 lSTH cells and HUVEs were cultured as previously described."
Antibodies. The antibody R59 was raised against recombinant truncated NFATp prepared from pNFATpXS.'' The antibody 67.5 was raised against peptide 72 of purified mouse NFATp." These antibodies were a gift from A. Rao" and cross-react between human and mouse NFATp. The oct-l antibody was a gift from R. Stunn (Centre for Molecular Biology and Biotechnology, Brisbane, Australia), Gel electrophoretic mobility shift assays. Gel shift assays of nuclear extracts were essentially as previously described* and used 0.2 ng of "P-labeled probe, 5 pg of nuclear protein, and 2 pg of poly(d1-dC) in a 15-pL vol. Nuclear extracts were prepared as previously described' from unstimulated cells and cells stimulated for 2 to 3 hours with 20 ng/mL PMA and 2 pmol/L A23187 (I) in the presence and absence of 0.1 pmoVL CsA. CsA was added 10 minutes before the addition of PMA and A23 187. Assays of recombinant proteins differed in that they used 200 ng poly(d1-dC), 4 mmoVL dithiothreitol and 0.3 mg/rnL bovine serum albumin together with 0.5 ng NFATp, 10 ng NF-KB p50, or 0.07 pL NF-KB p65. The NFATp was a 293-amino acid truncated derivative of NFATp containing the DNA-binding domain and was prepared from the plasmid pQE-31#1 (a gift from A. Rao), which is derived from pNFATpXS,'* by expression in Escherichia coli and chromatography on Quiagen Niz+ NTA agarose according to manufacturer's instructions. NF-KB p50 was purchased from Promega (Madison, WI), while the NF-KB p65 used here was a gift of purified recombinant truncated protein (amino acids 1-313) supplied by S. Gerondakis (Walter and Eliza Hall Institute, Melbourne, Australia).zR GM-CSF enzyme-linked immunosorbent assay. GM-CSF protein concentrations in cell culture supernatants were determined according to manufacturer's instructions using a human GM-CSF enzyme-linked immunosorbent assay (ELISA) kit supplied by R & D Systems (Minneapolis, MN). Supernatants were harvested from cultures containing 2 X IO5 cells seeded in 24-well trays with 400 pL medium. Cultures were initially incubated for 24 hours and then activated for 16 hours as indicated.
GM-CSF mRNA assays. GM-CSF mRNA levels were assayed as previously described' after stimulation of cells for 8 hours with 20 ng/mL PMA and 2 pmol/L A23187 (I) in the presence and absence of 0.1 pnol/L CsA. Briefly, RNA was prepared by the guanidine lysis method and assayed by RNase protection assay. Each hybridization reaction contained probes for both the GM-CSF and the constitutively expressed glyceraldehyde-3-phosphate dehydrogenase (GAPDH) genes, and the levels of GM-CSF expression were expressed relative to GAPDH.
DNase I hypersensitive site analysis. DNase I hypersensitive sites (DH) sites in C1 lSTH cells, HUVEs, Jurkat cells, and peripheral blood T lymphocytes were assayed as described* after stimulating the cells for 4 to 6 hours with 20 ng/mL PMA and 2 pmol/L A23187 (I) or 100 U/mL TNF-a in the presence and absence of 0.1 pmoVL CsA. Filters were first hybridized with the GM-CSF probe? AGAAGCTTC; IgK NF-KB, AACAGAGGGGACTTTCCGAGGFor personal use only. on October 22, 2017. by guest www.bloodjournal.org From then stripped by washing in 50% formamide at 65"C, before rehybridizing with the E-selectin probe. The E-selectin probe was a 1.7-kb BgnYEcoRI fragment normally located 1.3 to 3 kb downstream of the human E-selectin gene transcription start site, and was a gift from T. Collins (Brigham and Women's Hospital, Boston, MA). T lymphocytes were freshly purified from peripheral blood by Ficoll centrifugation to isolate mononuclear cells, elutriation to remove monocytes, and nylon wool chromatography to remove B cells.
Transfection assays. Luciferase reporter gene activities were determined as previously described by transfecting 20 pg of each plasmid construct into 1 X lo6 C1 lSTH cells by the diethylaminoethyl (DEAE) dextran procedure36 and measuring luciferase expression" after stimulation with 2 pmoK A23 187 (I) and 20 ng/mL PMA for 9 hours in the presence and absence of 0.1 pmoK CsA.
Neutrophil adhesion assays. Neutrophil adhesion assays were performed as previously de~cribed.~~ Briefly, confluent monolayers of CllSTH cells were incubated with 100 UlmL TNF-a in the presence or absence of 1 pmoK CsA. After 4 hours' activation, "Cr-labeled neutrophils (9 X lo5 cpm) were added and incubated at room temperature (approximately 22T) for 15 minutes. After several washes with medium, neutrophil adherence was estimated by measuring bound 5'Cr.
E-selectin and VCAM-I expression. Cell surface expression of E-selectin and VCAM-I on Cl ISTH cells was determined by flow cytometric (FACS) analysis using specific antibodies for E-selectin and VCAM-l, as previously described.36 Before analysis, cells were stimulated for 4 hours with different combinations 100 U/mL I F N -7 , 100 UlmL TNF-a, 20 ng/mL PMA, 2 pmovL A23187 (I), and 10 pmom forskolin.
RESULTS
Activated endothelial cells express NFAT.
CsA is a potent immunosuppressive drug known to function in T cells by inhibiting induction of the transcription factor NFAT. Although there have been no previous reports of NFAT in endothelial cells, CsA is used as an antiinflammatory agent, and some of its actions could be mediated by suppression of factors in the endothelium. Therefore, we have examined whether NFAT can be induced in endothelial cells by pathways known to activate NFAT in T cells. To this end, we stimulated C1 lSTH cells and passaged HUVEs with a combination of the phorbol ester PMA and the calcium ionophore A23187. These signals mimic the phospholipase C driven activation of protein kinase C and increase in cytosolic Ca2+ and induce the AP-I and NFATpk components of NFAT, respectively.
We performed gel electrophoretic mobility shift assays of nuclear extracts prepared from activated HUVEs and C1 ISTH cells using the GM-CSF enhancer GM430 sequence as a probe for NFATpk binding (lefthand panel in Fig 1) and the human IL-2 gene distal NFAT site as a probe for NFAT (righthand panel in Fig 1) . The IL-2 site served as the prototypic NFAT site most commonly used to assay for the presence of NFAT in T cells as it cooperatively binds AP-1 and NFATpIc to form NFAT complexe~.~ The GM430 site is a high-affinity NFATp site that is able to associate strongly with the NFATp/c component of NFAT independently of AP-1 . 9 Significantly, nuclear extracts from HUVEs and C l ISTH cells both formed inducible NFATpk-like complexes with the GM430 element and NFAT-like complexes with the IL-2 NFAT site that comigrated with Jurkat T-cell complexes in gel mobility shift assays (Fig 1) . AS in T cells, CsA completely inhibited the induction of these endothelial cell NFAT and NFATpk-like complexes (Fig 1) . Furthermore, complex formation with both probes was completely inhibited when either the IL-2 or GM430 NFAT elements were included as DNA competitors, but only partially inhibited when an unrelated competitor (X) was used.
NFATp appeared to be the major protein contributing to NFATpk-like complexes with the GM430 probe in C 1 1 STH and HUVE extracts as antibodies raised against either recombinant NFATp or to an NFATp peptide specifically inhibited formation of or super-shifted NFATp-like complexes as efficiently as they did with Jurkat cell extracts (Fig 2) . Addition of a 5-to 20-fold greater amount of oct-l antiserum had little effect on NFATp complex formation with the endothelial cell nuclear extracts. As the 67.1 NFATp antibody was raised against a peptide not conserved in NFATc, there appeared to be little or no NFATc present in either the endothelial cell or the Jurkat cell extracts employed in this study.
NFATp induction in endothelial cells may require a Ca2+ signal not provided by proinflammatory cytokines, as TNFa did not induce NFATp (data not shown). In contrast, TNFa was a more efficient inducer of NF-KB in endothelial cells than PMA and A23187 (data not shown).
GM-CSF expression is regulated by CsA in endothelial cells. If NFATp regulates gene expression in endothelial cells then GM-CSF gene activation via Ca2+ pathways in endothelial cells should also be CsA-sensitive. To explore this possibility, we examined GM-CSF synthesis in four independent lines of passaged HUVEs. As in T cells, the level of GM-CSF secretion by HUVEs was increased 100-fold by the combined actions of the phorbol ester PMA and the calcium ionophore A23 187 ( P" ,  Fig 3) . For each of the four lines of activated HUVEs, there was a decrease in GM-CSF expression in the presence of 0.1 pmoUL CsA, with an average reduction of 50%.
As we anticipated that CsA would inhibit GM-CSF at the transcriptional level, we also performed RNase protection assays of GM-CSF mRNA in HUVEs and CllSTH cells. Just as we observed for GM-CSF protein synthesis, GM-CSF mRNA was strongly induced in both HUVEs and CllSTH cells by PMA and A23187 (Fig 4) . GM-CSF mRNA induction required calcium ionophore as well PMA, as sixfold less GM-CSF mRNA was detected in the presence of PMA alone. In the presence of 0.1 pmoVL CsA the induction of GM-CSF mRNA was reduced by 65% in HUVEs and 56% in C1 lSTH cells (Fig 4) . This inhibition appeared to be specific, as we observed no effect of CsA on K-8 expression in endothelial cells (data not shown). CsA also appeared to have little effect on induction of GM-CSF expression by pathways that do not use Ca2+. Hence, CsA had no significant influence on induction of GM-CSF mRNA or protein expression in endothelial cells activated with TNFa (data not shown).
The GM-CSF enhancer exists as a DNaseI hypersensitive site in endothelial cells. In T cells, the GM-CSF enhancer exists as an inducible CsA-sensitive DNaseI hypersensitive (DH) site that spans at least two NFAT site^.^'^ To identify a role for this enhancer in the GM-CSF locus in endothelial cells, we examined DH sites upstream of the GM-CSF gene. These analyses were performed both in Cl ISTH cells ( Fig   5A) and in passaged HUVEs (Fig 5B) .
We located two DH sites that coincided with the proximal promoter and the previously defined enhancer 3 kb upstream of the gene. The DH site located within the promoter ap- peared as a constitutive site in both Cl I STH cells (Fig 5A) and HUVEs (Fig 5B) . Although not detected in Jurkat T cells, this site also appeared as a DH site in activated T lymphocytes (Fig 5B) . The DH site within the enhancer appeared as a weak site before activation and was strongly induced in the presence of the coactivators PMA and A23 I87 in both C1 ISTH cells and HUVEs. The DH site existed as a broad region 2.8 to 3.0 kb upstream of the GM-CSF gene, thus resembling the DH site induced in T cells. Significantly, induction of this DH site was reduced by about 70% in the presence of 0.1 pmol/L CsA, which had no effect on the promoter DH site (Fig 5A) . We also examined endothelial cells activated by TNF-a, but observed that this cytokine was not a significant inducer of any DH sites within the GM-CSF locus (data not shown).
The GM-CSF enhancer contributes to GM-CSF activation in endothelial cells. To determine whether the upstream enhancer was required for efficient GM-CSF promoter activation in endothelial cells, the enhancer was coupled to the GM-CSF promoter in a luciferase reporter gene plasmid. On transfection into C1 ISTH cells and stimulation with the coactivators PMA and A23187, the enhancer supported a fivefold greater induction of luciferase gene expression than was obtained with a luciferase gene driven by the GM-CSF promoter alone (Fig 6) . Furthermore, this induction was suppressed by about 60% in the presence of CsA.
CsA inhibits neutrophil adhesion to activated endothelial cells. Having found that CsA could suppress cytokine gene expression, we next examined whether CsA could influence neutrophil adhesion to activated endothelial cells. Neutrophils become involved at the earliest stages during the progression of inflammation and are also one of the cell types activated by GM-CSF.
In the presence of TNF-a, we observed an approximately sixfold increase in the adherence of neutrophils to a confluent monolayer of C1 ISTH cells ( E-selectin expression is suppressed by CsA in endothelial cells. To determine which leukocyte adhesion molecules on endothelial cells might be suppressed by CsA, we examined the regulation of E-selectin and VCAM-I expression in C1 lSTH cells. E-selectin can interact with receptors on neutrophils, eosinophils, monocytes, and subsets of T cells and is an important regulator of both acute and chronic inflammation.23.24 VCAM-l plays a major role in the adherence of monocytes and lymphocytes to endothelial cells. 23 We first showed that E-selectin was induced in C1 lSTH cells in the expected fashion by either TNF-a or a combination of PMA and A23 187 (PMAII) (Fig 7) . IFN-y alone was unable to induce E-selectin expression, but greatly enhanced its activation by TNF-a. We also observed that the CAMP inducer forskolin was a potent inhibitor of TNF-a-inducible E-selectin expression in C l lSTH cells, as previously observed by others in HUVES.'~ On inclusion of increasing amounts of CsA, we observed up to a 40% decrease in the cell surface expression of Eselectin expression in C l l STH cells activated by either TNFa, TNF-a plus I F N , or PMA and A23 187 (Fig 7) . CsA reduced the expression obtained with PMA and A23187 to a level equivalent to that obtained with PMA alone. Furthermore, activation of E-selectin expression in the presence of PMA alone was essentially resistant to the effects of CsA.
Interestingly, CsA also did not suppress the component of TNF-a-inducible E-selectin expression that was resistant to forskolin. The effects of CsA on E-selectin expression appeared to be specific, as CsA had no effect on the induction of VCAM-l expression by any of the above agents (data not shown).
A CsA-sensitive DNaseI hyper-sensitive site exists in the E-selectin promoter. To search for regulatory elements that might account for the CsA-sensitivity of E-selectin gene expression, we screened the E-selectin locus for CsA-sensitive DH sites. For this purpose we reprobed the filter used in Fig 5 with an intragenic E-selectin probe.
DNaseI digestion of the E-selectin chromosomal locus produced additional 3.0-and 6.5-kb subfragments of the 9-kb EcoRI fragment, indicating that two DH sites existed upstream of the E-selectin gene in activated endothelial cells (Fig 8) . One DH site near the origin of transcription was induced by either TNF-a or a combination of PMA and A23187 in both Cl ISTH cells (Fig 8A) and HUVEs ( Fig  8B) and has also recently been detected by others:' The second DH site, located 3.5 kb upstream, appeared as a constitutive DH site. Significantly, the inducible but not the constitutive site, was suppressed by CsA (Fig 8A) , suggesting that CsA-sensitive transcriptional activation ele- ments existed in the proximal promoter. Both DH sites appeared to be endothelial cell specific as they did not appear in activated Jurkat cells or T cells (Fig 8B) or in a wide range of other cell types examined (data not shown).
CsA may suppress NF-KB activity in the E-selectin promoter. We examined the sequence of the E-selectin promoter seeking transcription factor binding sites that might be involved in DH site formation and be suppressed by CsA. Previous studies of E-selectin gene regulation have implicated an array of three NF-KB sites in the promoter as being crucial for activation of E-selectin expression,"0d' and these sites may be the most likely targets for the actions of CsA in this locus. Indeed, there is some evidence that NF-KB p50 and c-re1 expression is inhibitible by either CsA or FK506T" which might account for the 40% inhibition of E-selectin expression that occurs in the presence of CsA. Nevertheless, there is also evidence obtained with T cells that NFAT-like factors can in some cases associate with NF-&-like regulatory regions."
To determine whether NFAT or NF-KB proteins are more likely to account for the CsA-sensitivity of E-selectin expression, we examined binding of recombinant NFATp, NF-KB p50, and NF-KB p65 to the best characterized NF-KB site in the E-selectin promoter (PD14'), and to three control NFATp and NF-KB binding sites (Fig 9) . This particular E-selectin NF-KB site was the most proximal of the three NF-KB sites in the promoter and the one found to be the most essential for E-selectin promoter activity. As this element encompasses the sequence AGAGGAAA, it is also the E-selectin NF-KB site that most resembles binding sites for NFATP.'.~ As anticipated from earlier studies of T-cell nuclear extracts," both the IL-2 NFAT site and the IgK NF-KB site had the capacity to associate with all three proteins. This confirmed the view that NF-KB and NFATp have the poten- For personal use only. on October 22, 2017. by guest www.bloodjournal.org From NFATp and NF-KB. The indicated probes were incubated with 0.5 ng inducible DH site in the proximal region of the promoter appeared NFATp, 10 ng NF-wB p50, or 0.07 p L NF-KB p65. The probes corresas a 3.0-kb fragment, whereas an upstream constitutive DH site apponded t o t h e IL-2 promoter distal NFAT site," the K lg gene NF-KB peared as a 6.5-kb fragment. The membranes used in (AI and (B) are site." the E-selectin promoter proximal NF-KB site,u and the GM430 the same as those in Fig 3. high-affinity NFATp site from the GM-CSF enhancer.'
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For personal use only. on October 22, 2017. by guest www.bloodjournal.org From many early inflammatory events, and CsA, which is in widespread use as an immunosuppressive and antiinflammatory drug. Two important classes of molecules that are activated during the early stages of inflammation are the cytokines and adhesion molecules that direct the activation and trafficking of leukocytes that enter inflammatory lesions. We have concentrated on GM-CSF and E-selectin as potential targets for antiinflammatory actions of CsA in endothelial cells, and these are two molecules that might function in concert on neutrophils and eosinophils.
Surprisingly, we discovered that immunoregulatory mechanisms initially thought to be restricted to lymphoid cells also operated in endothelial cells. Hence, the T-cell transcription factor NFAT was induced in endothelial cells by pathways that in T cells are triggered by T-cell receptor and phospholipase C activation. CsA, an immunosuppressant previously thought to function primarily by inhibiting induction of NFAT and cytokine gene expression in T cells, also inhibited activation of NFAT in endothelial cells. The endothelial cell NFAT complexes were found to contain the protein NFATp, which has recently been reported to be expressed in both hematopoietic and nonhematopoietic cells," rather than NFATc, which is thought to be lymphoid-specific. Although there are few previous reports suggesting functions for NFAT outside of the T-cell lineage, a recent study has implicated NFAT as a factor required for TNF-a gene expression in B cells.45 Other studies have demonstrated that ligation of surface immunoglobulin results in CsA-sensitive induction of NFAT and activation of NFAT-responsive reporter genes in B cell^.^,^' GM-CSF is a proinflammatory cytokine having the potential to activate neutrophils, monocytes, and eosinophils. Of all the cytokines that can be expressed by endothelial cells, GM-CSF is perhaps the only one strongly inhibited by CsA in T cells. Therefore, we have explored the potential of CsA to act as an antiinflammatory agent working to suppress activation of myeloid cells by GM-CSF. We observed that CsA suppressed the Caz+-mediated activation of GM-CSF protein expression in endothelial cells by 50% and GM-CSF mRNA expression by approximately 60%.
To determine the molecular basis for the regulation of GM-CSF expression in endothelial cells, we examined the functions of regulatory elements within the GM-CSF locus. Previous studies in T cells suggested that GM-CSF gene activation is mediated to a large extent by binding of NFAT to the upstream enhan~er,'.~ and binding of NFAT, AP-1, and NF-KB to the promoter.''-z0 In this study we found that the upstream enhancer was also required for efficient activation of the GM-CSF promoter in transfected endothelial cells, and that the activity of the promoter and enhancer was suppressed twofold in the presence of CsA. As seen previously in T cells, stimulation with PMA and A23187 led to chromatin structure changes within the enhancer that were suppressed by CsA. These observations may suggest a direct role for NFAT in the induction of the GM-CSF enhancer in endothelial cells.
In contrast to T cells, endothelial cells appeared to have only a partial dependence on NFAT for induction of GM-CSF expression. Although CsA completely suppressed induction of NFAT, it only partially suppressed the GM-CSF promoter and enhancer and GM-CSF mRNA and protein expression in endothelial cells. In T cells, CsA essentially eliminates GM-CSF gene expression.' Furthermore, TNF-a was a potent inducer of NF-KB and GM-CSF expression in endothelial cells, but was a poor activator of NFAT and an inefficient inducer of the DH site in the enhancer (data not shown). Therefore, it is likely that TNF-a induces GM-CSF expression by using factors that activate the promoter in the absence of NFAT. Interestingly, the GM-CSF promoter existed as a constitutive DH site in endothelial cells (Fig 5) , but not in T cells' (data not shown). Consequently, the GM-CSF promoter may exist in a primed state in cultured endothelial cells and have a reduced dependence on the enhancer for its activation.
We also found some evidence suggesting that CsA can inhibit endothelial cell functions by suppressing factors other than NFAT. E-selectin expression was inhibited by about 40% in the presence of CsA by a process unlikely to directly involve NFAT. The E-selectin promoter is activated principally by an array of NF-KB site^,^.^' which represented poor binding sites for NFATp. Furthermore, the suppression of E-selectin by CsA was not limited to activation pathways involving Ca". CsA reduced E-selectin expression by the same extent regardless of whether TNF-(U or PMNA23187 was used to induce expression. This was in marked contrast to the GM-CSF gene, which was suppressed by CsA when activated by PMNA23187, but not when activated by TNFa. CsA also suppressed induction of the DH site that forms over the array of NF-KB sites in the E-selectin promoter, suggesting that CsA may regulate members of the NF-KB family in endothelial cells. This suggestion is supported by reports that CsA and FK506 can partially suppress two NF-KB family members in lymphoid cells.43*" Indeed, the NF-KB p105/p50 gene promoter4' may itself be regulated by CsA, as it includes the sequence TGGACCGCATGA-CTCTA that closely resembles the NFAT consensus sequence.' Alternatively, CsA may suppress E-selectin expression at the posttranscriptional level, thus accounting for the ability of CsA to suppress distinct pathways to the same extent. However, E-selectin induction via PMA was not significantly influenced by CsA, arguing against a posttranscriptional mechanism.
The evidence accumulated in this study suggests that the ability of CsA to act as an antiinflammatory drug may be partly caused by direct effects on the endothelium. Although immune and inflammatory disorders clearly involve complex cytokine networks operating within a confederacy of immune and nonimmune cell types, there is a significant role that the endothelium plays in their progression. By suppressing GM-CSF and E-selectin expression in endothelial cells, CsA could reduce the extent to which neutrophils and eosinophils are recruited at sites of inflammation. In this study, the effective dose of CsA (0.1 p r n o a ) was well within the range of the plasma concentration of approximately 0.3 pmol/L CsA that is usually maintained therapeutically. Hence, this study may, in part, account for the reduction in neutrophil and eosinophil infiltration observed on treatment of disorders such as p s o r i a~i s~~*~' and asthma27s4' with CsA.
For personal use only. on October 22, 2017. by guest www.bloodjournal.org From
ACKNOWLEDGMENT
We are indebted to A. Rao for providing NFATp anti-sera and DNA clones for NFATp, Y. Khew-Goodall for the E-selectin NF-KB probe, and T. Collins for providing E-selectin DNA clones. We thank R. Himes, F. Jenkins, and F. Shannon for the luciferase reporter gene plasmids. We thank L. Noack for technical assistance with neutrophil adhesion assays and B. Stein for assistance with statistical analyses. We thank D. Gillis, Y. Khew-Goodall, and M.F. Shannon for helpful advice and critical reading of the manuscript.
